|
3SBio Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
3SBio Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Abbott Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Abbott Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Abbvie Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Abbvie Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Acorda Therapeutics Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Acorda Therapeutics Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Actavis Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Actavis Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Actelion Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Actelion Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Age Related Macular Degeneration - Pipeline Review, H2 2017 |
Dec 29 2017 |
537 |
Global |
$2,000.00 |
|
|
Alcon Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Alcon Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Alexion Pharmaceuticals Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Alexion Pharmaceuticals Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Alkermes Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Alkermes Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Allergan Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Allergan Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Allergic Rhinitis - 5EU Drug Forecast and Market Analysis to 2024 |
Sep 1 2015 |
187 |
Europe |
$6,995.00 |
|
|
Allergic Rhinitis - Current and Future Players |
Sep 1 2015 |
82 |
Global |
$2,995.00 |
|
|
Allergic Rhinitis - Japan Drug Forecast and Market Analysis to 2024 |
Sep 1 2015 |
174 |
Japan |
$4,995.00 |
|
|
Allergic Rhinitis - US Drug Forecast and Market Analysis to 2024 |
Sep 1 2015 |
173 |
USA |
$4,995.00 |
|
|
Alnylam Pharmaceuticals Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
|
Alnylam Pharmaceuticals Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents |
Feb 1 2016 |
144 |
Global |
$4,995.00 |
|
|
Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies |
Mar 1 2016 |
151 |
Asia Pacific |
$4,995.00 |
|
|
AMAG Pharmaceuticals Partnering Deals and Alliances 2010 to 2016 |
Oct 1 2016 |
100 |
Global |
$1,495.00 |
|
